You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIndapamide
Accession NumberDB00808  (APRD01031)
TypeSmall Molecule
GroupsApproved
DescriptionA benzamide-sulfonamide-indole. It is called a thiazide-like diuretic but structure is different enough (lacking the thiazo-ring) so it is not clear that the mechanism is comparable. [PubChem]
Structure
Thumb
Synonyms
Indapamid
Indapamida
Indapamide
Indapamidum
Metindamide
External Identifiers
  • RHC 2555
  • S 1520
  • SE 1520
  • USV 2555
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dom-indapamide Tablets 1.25mgTablet1.25 mgOralDominion Pharmacal1999-09-15Not applicableCanada
Dom-indapamide Tablets 2.5mgTablet2.5 mgOralDominion Pharmacal1999-09-15Not applicableCanada
IndapamideTablet1.25 mgOralSanis Health Inc2015-10-14Not applicableCanada
IndapamideTablet2.5 mgOralSanis Health IncNot applicableNot applicableCanada
IndapamideTablet2.5 mgOralSanis Health Inc2015-10-14Not applicableCanada
Indapamide Hemihydrate 1.25mg - TabTablet1.25 mgOralProval Pharma Division Of Servier Canada Inc1997-08-142012-02-13Canada
Indapamide Hemihydrate Tab 2.5mgTablet2.5 mgOralProval Pharma Division Of Servier Canada Inc1995-12-312012-02-13Canada
Indapamide-2.5Tablet2.5 mgOralPro Doc Limitee1997-04-302008-07-04Canada
Jamp-indapamideTablet1.25 mgOralJamp Pharma Corporation2011-10-17Not applicableCanada
Jamp-indapamideTablet2.5 mgOralJamp Pharma Corporation2011-10-17Not applicableCanada
LozideTablet1.25 mgOralServier Canada Inc1995-12-31Not applicableCanada
LozideTablet2.5 mgOralServier Canada Inc1982-12-31Not applicableCanada
Mylan-indapamideTablet2.5 mgOralMylan Pharmaceuticals Ulc1995-12-31Not applicableCanada
Mylan-indapamideTablet1.25 mgOralMylan Pharmaceuticals Ulc1999-05-10Not applicableCanada
Ntp-indapamideTablet2.5 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Nu-indapamideTablet1.25 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-indapamide - Tab 2.5mgTablet2.5 mgOralNu Pharm Inc1996-08-292012-09-04Canada
PHL-indapamideTablet2.5 mgOralPharmel Inc2002-05-28Not applicableCanada
PHL-indapamideTablet1.25 mgOralPharmel Inc2002-05-28Not applicableCanada
PMS-indapamideTablet1.25 mgOralPharmascience Inc1999-02-18Not applicableCanada
PMS-indapamideTablet2.5 mgOralPharmascience Inc1999-02-18Not applicableCanada
Pro-indapamideTablet2.5 mgOralPro Doc Limitee2008-07-04Not applicableCanada
Pro-indapamideTablet1.25 mgOralPro Doc Limitee2008-07-04Not applicableCanada
Riva-indapamide 1.25Tablet1.25 mgOralLaboratoire Riva Inc2003-03-11Not applicableCanada
Riva-indapamide 2.5 mgTablet2.5 mgOralLaboratoire Riva Inc2000-05-10Not applicableCanada
Teva-indapamideTablet2.5 mgOralTeva Canada Limited1997-05-04Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-indapamide 1.25 Mg TabletsTablet1.25 mgOralApotex Inc2002-11-08Not applicableCanada
Apo-indapamide 2.5mg TabletsTablet2.5 mgOralApotex Inc1996-10-02Not applicableCanada
IndapamideTablet, film coated2.5 mg/1OralMylan Institutional Inc.1996-05-01Not applicableUs
IndapamideTablet, film coated2.5 mg/1OralActavis Elizabeth LLC2007-01-02Not applicableUs
IndapamideTablet2.5 mg/1OralAmerigen Pharmaceuticals Inc.2016-10-06Not applicableUs
IndapamideTablet, film coated1.25 mg/1OralRebel Distributors Corp2010-01-18Not applicableUs
IndapamideTablet, film coated2.5 mg/1Oralbryant ranch prepack2007-01-02Not applicableUs
IndapamideTablet, film coated1.25 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-01-02Not applicableUs
IndapamideTablet, film coated1.25 mg/1OralActavis Elizabeth LLC2007-01-02Not applicableUs
IndapamideTablet, film coated1.25 mg/1OralAv Kare, Inc.2016-02-09Not applicableUs
IndapamideTablet, film coated1.25 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-07-12Not applicableUs
IndapamideTablet, film coated1.25 mg/1OralCarilion Materials Management1997-03-26Not applicableUs
IndapamideTablet, film coated1.25 mg/1OralMylan Pharmaceuticals Inc.1997-03-26Not applicableUs
IndapamideTablet, film coated2.5 mg/1OralAv Kare, Inc.2016-02-09Not applicableUs
IndapamideTablet2.5 mg/1OralREMEDYREPACK INC.2010-09-162016-10-13Us
IndapamideTablet, film coated2.5 mg/1OralMylan Pharmaceuticals Inc.1996-03-28Not applicableUs
IndapamideTablet1.25 mg/1OralAmerigen Pharmaceuticals Inc.2016-10-06Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ArifonServier
BajatenMerck
FludexServier
IndamolTeofarma
IpamixVisufarma
LozideServier
Lozolsanofi-aventis
NatrilixServier
NatrixKyoto Yakuhin
NoranatSandoz
TandixAzevedos
TertensifServier
VeroxilBaldacci
Brand mixtures
NameLabellerIngredients
Arcosyl PlusServier Canada Inc
Arcosyl Plus LdServier Canada Inc
Coversyl PlusServier Canada Inc
Coversyl Plus HdServier Canada Inc
Coversyl Plus LdServier Canada Inc
SaltsNot Available
Categories
UNIIF089I0511L
CAS number26807-65-8
WeightAverage: 365.835
Monoisotopic: 365.06008979
Chemical FormulaC16H16ClN3O3S
InChI KeyNDDAHWYSQHTHNT-UHFFFAOYSA-N
InChI
InChI=1S/C16H16ClN3O3S/c1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23)
IUPAC Name
4-chloro-N-(2-methyl-2,3-dihydro-1H-indol-1-yl)-3-sulfamoylbenzamide
SMILES
CC1CC2=CC=CC=C2N1NC(=O)C1=CC(=C(Cl)C=C1)S(N)(=O)=O
Pharmacology
IndicationFor the treatment of hypertension, alone or in combination with other antihypertensive drugs, as well as for the treatment of salt and fluid retention associated with congestive heart failure or edema from pregnancy (appropriate only in the management of edema of pathologic origin during pregnancy when clearly needed). Also used for the management of edema as a result of various causes.
Structured Indications
PharmacodynamicsIndapamide is an antihypertensive and a diuretic. It contains both a polar sulfamoyl chlorobenzamide moiety and a lipid- soluble methylindoline moiety. Indapamide bears a structural similarity to the triazide diuretics which are known to decrease vascular smooth muscle reactivity. However, it differs chemically from the thiazides in that it does not possess the thiazide ring system and contains only one sulfonamide group. Indapamide appears to cause vasodilation, probably by inhibiting the passage of calcium and other ions (sodium, potassium) across membranes. This same effect may cause hypokalcemia in susceptible individuals. Indapamide has also been shown to cause uterine myometrial relaxation in experimental animals. Overall, indapamide has an extra-renal antihypertensive action resulting in a decrease in vascular hyperreactivity and a reduction in total peripheral and arteriolar resistance.
Mechanism of actionIndapamide blocks the slow component of delayed rectifier potassium current (IKs) without altering the rapid component (IKr) or the inward rectifier current. Specifically it blocks or antagonizes the action the proteins KCNQ1 and KCNE1. Indapamide is also thought to stimulate the synthesis of the vasodilatory hypotensive prostaglandin PGE2.
TargetKindPharmacological actionActionsOrganismUniProt ID
Potassium voltage-gated channel subfamily KQT member 1Proteinyes
inhibitor
HumanP51787 details
Potassium voltage-gated channel subfamily E member 1Proteinyes
inhibitor
HumanP15382 details
Related Articles
AbsorptionRapidly absorbed from gastrointestinal tract.
Volume of distributionNot Available
Protein binding71-79%
Metabolism

Primarily hepatic. Indapamide is an extensively metabolized drug with only about 7+ACU- of the total dose administered, recovered in the urine as unchanged drug during the first 48 hours after administration.

SubstrateEnzymesProduct
Indapamide
Indapamide metabolite M5Details
Indapamide metabolite M5
Indapamide metabolite M4Details
Indapamide metabolite M4
Not Available
Indapamide metabolite M2Details
Indapamide
Indapamide metabolite M1Details
Indapamide metabolite M1
Indapamide metabolite M3Details
Indapamide metabolite M3
Indapamide metabolite M2Details
Indapamide
Indapamide epoxide intermediateDetails
Indapamide epoxide intermediate
Indapamide metabolite M6Details
Route of eliminationIndapamide is an extensively metabolized drug, with only about 7% of the total dose administered, recovered in the urine as unchanged drug during the first 48 hours after administration.
Half life14 hours (biphasic)
ClearanceNot Available
ToxicitySide effects include electrolyte imbalance (potassium or salt depletion due to too much fluid loss), nausea, stomach disorders, vomiting, weakness
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Indapamide Action PathwayDrug actionSMP00110
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Indapamide.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Indapamide.Experimental, Illicit
4-Androstenedione4-Androstenedione may increase the hypokalemic activities of Indapamide.Experimental, Illicit
5-androstenedione5-androstenedione may increase the hypokalemic activities of Indapamide.Experimental, Illicit
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Indapamide.Experimental
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Indapamide.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Indapamide is combined with Acebutolol.Approved
AceclofenacThe therapeutic efficacy of Indapamide can be decreased when used in combination with Aceclofenac.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Indapamide.Withdrawn
AcetovanilloneThe therapeutic efficacy of Indapamide can be decreased when used in combination with Acetovanillone.Investigational
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Indapamide is combined with Acetyldigitoxin.Approved
Acetylsalicylic acidThe therapeutic efficacy of Indapamide can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AclidiniumThe serum concentration of Indapamide can be increased when it is combined with Aclidinium.Approved
AdapaleneThe therapeutic efficacy of Indapamide can be decreased when used in combination with Adapalene.Approved
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Indapamide.Experimental
AlclometasoneAlclometasone may increase the hypokalemic activities of Indapamide.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Indapamide.Approved
AldosteroneAldosterone may increase the hypokalemic activities of Indapamide.Experimental
AlfacalcidolIndapamide may increase the hypercalcemic activities of Alfacalcidol.Approved, Nutraceutical
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Indapamide.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Indapamide.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Indapamide is combined with Aliskiren.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Indapamide.Approved
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Indapamide.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Indapamide.Experimental, Illicit
AlprenololIndapamide may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanIndapamide may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmcinonideAmcinonide may increase the hypokalemic activities of Indapamide.Approved
AmifostineIndapamide may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Indapamide.Approved
AmiodaroneThe metabolism of Indapamide can be decreased when combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Indapamide.Approved
AmobarbitalAmobarbital may increase the orthostatic hypotensive activities of Indapamide.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Indapamide is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Indapamide is combined with Amyl Nitrite.Approved
AnagrelideIndapamide may increase the QTc-prolonging activities of Anagrelide.Approved
AnecortaveAnecortave may increase the hypokalemic activities of Indapamide.Investigational
AnisodamineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Anisodamine.Investigational
Anisotropine MethylbromideThe serum concentration of Indapamide can be increased when it is combined with Anisotropine Methylbromide.Approved
AntipyrineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Antipyrine.Approved
AnvirzelThe risk or severity of adverse effects can be increased when Indapamide is combined with Anvirzel.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Indapamide is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Indapamide is combined with Apraclonidine.Approved
ApremilastThe therapeutic efficacy of Indapamide can be decreased when used in combination with Apremilast.Approved, Investigational
AprepitantThe serum concentration of Indapamide can be increased when it is combined with Aprepitant.Approved, Investigational
ArbutamineArbutamine may increase the hypokalemic activities of Indapamide.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Indapamide.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Indapamide.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Indapamide is combined with Arotinolol.Approved
Arsenic trioxideIndapamide may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherIndapamide may increase the QTc-prolonging activities of Artemether.Approved
AsenapineIndapamide may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirThe metabolism of Indapamide can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Indapamide.Approved
AtomoxetineThe metabolism of Indapamide can be decreased when combined with Atomoxetine.Approved
Atracurium besylateThe serum concentration of Indapamide can be increased when it is combined with Atracurium besylate.Approved
AtropineThe serum concentration of Indapamide can be increased when it is combined with Atropine.Approved, Vet Approved
AzapropazoneThe therapeutic efficacy of Indapamide can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Indapamide is combined with Azilsartan medoxomil.Approved
AzithromycinIndapamide may increase the QTc-prolonging activities of Azithromycin.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Indapamide.Investigational
BalsalazideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Balsalazide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Indapamide.Approved
BarbexacloneBarbexaclone may increase the orthostatic hypotensive activities of Indapamide.Experimental
BarbitalBarbital may increase the orthostatic hypotensive activities of Indapamide.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Indapamide is combined with Barnidipine.Approved
BeclomethasoneBeclomethasone may increase the hypokalemic activities of Indapamide.Investigational
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Indapamide.Approved, Investigational
BedaquilineIndapamide may increase the QTc-prolonging activities of Bedaquiline.Approved
BenactyzineThe serum concentration of Indapamide can be increased when it is combined with Benactyzine.Withdrawn
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Indapamide.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Indapamide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Indapamide.Withdrawn
BenoxaprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzatropineThe serum concentration of Indapamide can be increased when it is combined with Benzatropine.Approved
BepridilIndapamide may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneBetamethasone may increase the hypokalemic activities of Indapamide.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Indapamide.Approved
BethanidineBethanidine may increase the hypotensive activities of Indapamide.Approved
Betulinic AcidThe therapeutic efficacy of Indapamide can be decreased when used in combination with Betulinic Acid.Investigational
BexaroteneThe serum concentration of Indapamide can be decreased when it is combined with Bexarotene.Approved, Investigational
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Indapamide.Experimental, Illicit, Withdrawn
BimatoprostIndapamide may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BiperidenThe serum concentration of Indapamide can be increased when it is combined with Biperiden.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Indapamide.Approved
BoceprevirThe metabolism of Indapamide can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Indapamide can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Indapamide can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Indapamide is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Indapamide.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Indapamide.Approved
BromfenacThe therapeutic efficacy of Indapamide can be decreased when used in combination with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Indapamide is combined with Bromocriptine.Approved, Investigational
BucillamineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Bucillamine.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Indapamide.Approved
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Indapamide.Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Indapamide is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Indapamide is combined with Bupivacaine.Approved, Investigational
BupranololIndapamide may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Indapamide.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Indapamide.Approved, Illicit, Vet Approved
CalcidiolIndapamide may increase the hypercalcemic activities of Calcidiol.Approved, Nutraceutical
CalcipotriolIndapamide may increase the hypercalcemic activities of Calcipotriol.Approved
CalcitriolIndapamide may increase the hypercalcemic activities of Calcitriol.Approved, Nutraceutical
CalciumIndapamide may decrease the excretion rate of Calcium which could result in a higher serum level.Nutraceutical
Calcium AcetateIndapamide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
Calcium carbonateIndapamide may decrease the excretion rate of Calcium carbonate which could result in a higher serum level.Approved
Calcium ChlorideIndapamide may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.Approved
Calcium citrateIndapamide may decrease the excretion rate of Calcium citrate which could result in a higher serum level.Approved
Calcium glubionateIndapamide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved
Calcium GluceptateIndapamide may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved
Calcium gluconateIndapamide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved, Vet Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Indapamide is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Indapamide.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Indapamide.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Indapamide is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Indapamide is combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Indapamide is combined with Carbetocin.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Indapamide.Illicit, Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Indapamide.Withdrawn
CarprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Indapamide.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Indapamide is combined with Carvedilol.Approved, Investigational
CastanospermineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Indapamide can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Indapamide.Approved, Investigational
CeritinibThe serum concentration of Indapamide can be increased when it is combined with Ceritinib.Approved
ChloroquineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Indapamide is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenoxamineThe serum concentration of Indapamide can be increased when it is combined with Chlorphenoxamine.Withdrawn
ChlorpromazineIndapamide may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Indapamide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Indapamide.Approved
CholecalciferolIndapamide may increase the hypercalcemic activities of Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Indapamide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Indapamide.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Indapamide.Experimental
CilazaprilThe risk or severity of adverse effects can be increased when Indapamide is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Indapamide is combined with Cilnidipine.Approved
CiprofloxacinIndapamide may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideIndapamide may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramIndapamide may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinThe metabolism of Indapamide can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Indapamide can be decreased when combined with Clemastine.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Indapamide.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Indapamide is combined with Clevidipine.Approved
ClobetasolClobetasol may increase the hypokalemic activities of Indapamide.Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Indapamide.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Indapamide.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Indapamide is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Indapamide is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Indapamide.Approved
ClonixinThe therapeutic efficacy of Indapamide can be decreased when used in combination with Clonixin.Approved
ClotrimazoleThe metabolism of Indapamide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineIndapamide may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe metabolism of Indapamide can be decreased when combined with Cobicistat.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Indapamide.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Indapamide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Indapamide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Indapamide can be increased when it is combined with Conivaptan.Approved, Investigational
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Indapamide.Approved
CrizotinibIndapamide may increase the QTc-prolonging activities of Crizotinib.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Indapamide.Approved
CurcuminThe therapeutic efficacy of Indapamide can be decreased when used in combination with Curcumin.Investigational
CyclopentolateThe serum concentration of Indapamide can be increased when it is combined with Cyclopentolate.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Indapamide can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Indapamide.Approved
D-LimoneneThe therapeutic efficacy of Indapamide can be decreased when used in combination with D-Limonene.Investigational
DabrafenibThe serum concentration of Indapamide can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Indapamide is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the hyponatremic activities of Indapamide.Investigational
DarifenacinThe serum concentration of Indapamide can be increased when it is combined with Darifenacin.Approved, Investigational
DarunavirThe metabolism of Indapamide can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Indapamide can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinIndapamide may increase the hypotensive activities of Debrisoquin.Approved
DeferasiroxThe serum concentration of Indapamide can be decreased when it is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfatedehydroepiandrosterone sulfate may increase the hypokalemic activities of Indapamide.Investigational
DelavirdineThe metabolism of Indapamide can be decreased when combined with Delavirdine.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Indapamide.Investigational
DeserpidineIndapamide may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Indapamide is combined with Desflurane.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Indapamide is combined with Deslanoside.Approved
DesloratadineThe serum concentration of Indapamide can be increased when it is combined with Desloratadine.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Indapamide.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Indapamide.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Indapamide.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the hyponatremic activities of Indapamide.Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Indapamide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Indapamide.Vet Approved
DexetimideThe serum concentration of Indapamide can be increased when it is combined with Dexetimide.Withdrawn
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Indapamide.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Indapamide.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Indapamide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Indapamide.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Indapamide.Approved
DiazoxideThe risk or severity of adverse effects can be increased when Indapamide is combined with Diazoxide.Approved
DiclofenacThe therapeutic efficacy of Indapamide can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Diclofenamide.Approved
DicyclomineThe serum concentration of Indapamide can be increased when it is combined with Dicyclomine.Approved
DiflorasoneDiflorasone may increase the hypokalemic activities of Indapamide.Approved
DiflunisalThe therapeutic efficacy of Indapamide can be decreased when used in combination with Diflunisal.Approved
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Indapamide.Approved
DifluprednateDifluprednate may increase the hypokalemic activities of Indapamide.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Indapamide is combined with Digitoxin.Approved
DigoxinThe risk or severity of adverse effects can be increased when Indapamide is combined with Digoxin.Approved
DihydralazineIndapamide may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Indapamide.Approved, Illicit
DihydroergotamineThe metabolism of Indapamide can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Indapamide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Indapamide.Experimental, Illicit
DihydrotachysterolIndapamide may increase the hypercalcemic activities of Dihydrotachysterol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Indapamide.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Indapamide is combined with Dinutuximab.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Indapamide.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Indapamide.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Indapamide is combined with Dipyridamole.Approved
DisopyramideIndapamide may increase the QTc-prolonging activities of Disopyramide.Approved
DobutamineDobutamine may increase the hypokalemic activities of Indapamide.Approved
DofetilideIndapamide may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronIndapamide may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneIndapamide may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DorzolamideIndapamide may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Indapamide.Approved
DoxercalciferolIndapamide may increase the hypercalcemic activities of Doxercalciferol.Approved
DoxycyclineThe metabolism of Indapamide can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Indapamide.Investigational
DronedaroneIndapamide may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolIndapamide may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DroxicamThe therapeutic efficacy of Indapamide can be decreased when used in combination with Droxicam.Approved
DroxidopaDroxidopa may increase the hypokalemic activities of Indapamide.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Indapamide.Approved
DuloxetineIndapamide may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe therapeutic efficacy of Indapamide can be decreased when used in combination with Duvelisib.Investigational
E6201The therapeutic efficacy of Indapamide can be decreased when used in combination with E6201.Investigational
EbselenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Ebselen.Investigational
EfavirenzThe serum concentration of Indapamide can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineIndapamide may increase the hypotensive activities of Efonidipine.Approved
EliglustatIndapamide may increase the QTc-prolonging activities of Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Indapamide is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Indapamide.Approved, Vet Approved
EnalaprilatIndapamide may increase the hypotensive activities of Enalaprilat.Approved
EnzalutamideThe serum concentration of Indapamide can be decreased when it is combined with Enzalutamide.Approved
EphedraEphedra may increase the hypokalemic activities of Indapamide.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Indapamide.Approved, Vet Approved
EpirizoleThe therapeutic efficacy of Indapamide can be decreased when used in combination with Epirizole.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Indapamide.Approved
EpoprostenolIndapamide may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Indapamide is combined with Eprosartan.Approved
EquileninEquilenin may increase the hypokalemic activities of Indapamide.Experimental
EquilinEquilin may increase the hypokalemic activities of Indapamide.Approved
ErgocalciferolIndapamide may increase the hypercalcemic activities of Ergocalciferol.Approved, Nutraceutical
ErythromycinIndapamide may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramIndapamide may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Indapamide can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Indapamide.Approved
EstroneEstrone may increase the hypokalemic activities of Indapamide.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Indapamide.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Indapamide is combined with Etacrynic acid.Approved
EtanerceptThe therapeutic efficacy of Indapamide can be decreased when used in combination with Etanercept.Approved, Investigational
EthanolEthanol may increase the orthostatic hypotensive activities of Indapamide.Approved
EthopropazineThe serum concentration of Indapamide can be increased when it is combined with Ethopropazine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Indapamide.Approved, Illicit
EtodolacThe therapeutic efficacy of Indapamide can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Indapamide can be decreased when used in combination with Etofenamate.Approved
EtoperidoneEtoperidone may increase the hyponatremic activities of Indapamide.Approved
EtoricoxibThe therapeutic efficacy of Indapamide can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Indapamide.Illicit, Vet Approved
EtravirineThe serum concentration of Indapamide can be decreased when it is combined with Etravirine.Approved
Evening primrose oilThe therapeutic efficacy of Indapamide can be decreased when used in combination with Evening primrose oil.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Indapamide.Approved, Investigational
exisulindThe therapeutic efficacy of Indapamide can be decreased when used in combination with exisulind.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Indapamide is combined with Felodipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Indapamide.Approved
FenoprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Fenoprofen.Approved
FenoterolFenoterol may increase the hypokalemic activities of Indapamide.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Indapamide.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Indapamide can be increased when it is combined with Fesoterodine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Indapamide is combined with Fimasartan.Approved
FlecainideIndapamide may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FloctafenineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Floctafenine.Approved, Withdrawn
fluasteronefluasterone may increase the hypokalemic activities of Indapamide.Investigational
FluconazoleThe metabolism of Indapamide can be decreased when combined with Fluconazole.Approved
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Indapamide.Approved
FlumethasoneFlumethasone may increase the hypokalemic activities of Indapamide.Approved, Vet Approved
FlunisolideFlunisolide may increase the hypokalemic activities of Indapamide.Approved, Investigational
FlunixinThe therapeutic efficacy of Indapamide can be decreased when used in combination with Flunixin.Vet Approved
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Indapamide.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Indapamide.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Indapamide.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Indapamide.Approved
FluoxetineIndapamide may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolIndapamide may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluprednideneFluprednidene may increase the hypokalemic activities of Indapamide.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Indapamide.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Indapamide.Approved
FlurbiprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Flurbiprofen.Approved, Investigational
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Indapamide.Approved
Fluticasone PropionateFluticasone Propionate may increase the hypokalemic activities of Indapamide.Approved
FluvoxamineThe metabolism of Indapamide can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneFormestane may increase the hypokalemic activities of Indapamide.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Indapamide.Approved, Investigational
FosamprenavirThe metabolism of Indapamide can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Indapamide can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Indapamide.Approved
FosphenytoinThe metabolism of Indapamide can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Indapamide.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Indapamide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Indapamide can be increased when it is combined with Fusidic Acid.Approved
Gadobenic acidIndapamide may increase the QTc-prolonging activities of Gadobenic acid.Approved
Gallamine TriethiodideThe serum concentration of Indapamide can be increased when it is combined with Gallamine Triethiodide.Approved
GemifloxacinIndapamide may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Indapamide.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Indapamide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Indapamide.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Indapamide.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Indapamide.Approved
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Indapamide.Approved
GlycopyrroniumThe serum concentration of Indapamide can be increased when it is combined with Glycopyrronium.Approved, Investigational, Vet Approved
GoserelinIndapamide may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronIndapamide may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanabenzGuanabenz may increase the hypotensive activities of Indapamide.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Indapamide.Approved
GuanethidineIndapamide may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Indapamide is combined with Guanfacine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Indapamide.Investigational
HaloperidolIndapamide may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Indapamide is combined with Halothane.Approved, Vet Approved
HE3286HE3286 may increase the hypokalemic activities of Indapamide.Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Indapamide.Approved, Illicit
HexamethoniumThe serum concentration of Indapamide can be increased when it is combined with Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the orthostatic hypotensive activities of Indapamide.Approved
HigenamineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Higenamine.Investigational
HMPL-004The therapeutic efficacy of Indapamide can be decreased when used in combination with HMPL-004.Investigational
HomatropineThe serum concentration of Indapamide can be increased when it is combined with Homatropine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Indapamide.Approved
HydralazineThe risk or severity of adverse effects can be increased when Indapamide is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Indapamide is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Indapamide.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Indapamide.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Indapamide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Indapamide.Approved, Illicit
HyoscyamineThe serum concentration of Indapamide can be increased when it is combined with Hyoscyamine.Approved
IbuprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Indapamide can be decreased when used in combination with Ibuproxam.Withdrawn
IbutilideIndapamide may increase the QTc-prolonging activities of Ibutilide.Approved
IcatibantThe therapeutic efficacy of Indapamide can be decreased when used in combination with Icatibant.Approved
IdelalisibThe serum concentration of Indapamide can be increased when it is combined with Idelalisib.Approved
IloperidoneIndapamide may increase the QTc-prolonging activities of Iloperidone.Approved
IloprostIloprost may increase the hypotensive activities of Indapamide.Approved, Investigational
ImatinibThe metabolism of Indapamide can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Indapamide is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Indapamide is combined with Imipramine.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Indapamide.Approved
IndalpineIndalpine may increase the hyponatremic activities of Indapamide.Investigational, Withdrawn
IndenololIndapamide may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Indapamide can be decreased when combined with Indinavir.Approved
IndomethacinThe therapeutic efficacy of Indapamide can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminIndapamide may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Indapamide.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Indapamide.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Indapamide.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Indapamide.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Indapamide.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Indapamide.Approved
Ipratropium bromideThe serum concentration of Indapamide can be increased when it is combined with Ipratropium bromide.Approved
IproclozideIproclozide may increase the hypotensive activities of Indapamide.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Indapamide.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Indapamide is combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Indapamide can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Indapamide.Approved
IsoetarineIsoetarine may increase the hypokalemic activities of Indapamide.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Indapamide is combined with Isoflurane.Approved, Vet Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Indapamide.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Indapamide is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Indapamide is combined with Isosorbide Mononitrate.Approved
IsoxicamThe therapeutic efficacy of Indapamide can be decreased when used in combination with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Indapamide is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Indapamide.Approved
IstaroximeIstaroxime may increase the hypokalemic activities of Indapamide.Investigational
ItraconazoleThe metabolism of Indapamide can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineIndapamide may increase the arrhythmogenic activities of Ivabradine.Approved
IvacaftorThe serum concentration of Indapamide can be increased when it is combined with Ivacaftor.Approved
KebuzoneThe therapeutic efficacy of Indapamide can be decreased when used in combination with Kebuzone.Experimental
KetanserinIndapamide may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Indapamide.Approved
KetoconazoleThe metabolism of Indapamide can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Indapamide can be decreased when used in combination with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Indapamide.Approved
LacidipineIndapamide may increase the hypotensive activities of Lacidipine.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Indapamide.Approved, Investigational
LeflunomideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Leflunomide.Approved, Investigational
LenvatinibIndapamide may increase the QTc-prolonging activities of Lenvatinib.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Indapamide.Approved, Investigational
LeuprolideIndapamide may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Indapamide is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Indapamide is combined with Levobupivacaine.Approved
LevodopaIndapamide may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinIndapamide may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Indapamide.Approved
LevomilnacipranLevomilnacipran may increase the hyponatremic activities of Indapamide.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Indapamide.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Indapamide is combined with Levosimendan.Approved, Investigational
LicoriceLicorice may increase the hypokalemic activities of Indapamide.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Indapamide.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Indapamide.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Indapamide.Approved, Investigational
LisofyllineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Lisofylline.Investigational
LithiumIndapamide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Indapamide.Illicit
LofexidineIndapamide may increase the hypotensive activities of Lofexidine.Approved, Investigational
LopinavirThe metabolism of Indapamide can be decreased when combined with Lopinavir.Approved
LornoxicamThe therapeutic efficacy of Indapamide can be decreased when used in combination with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Indapamide.Approved
LovastatinThe metabolism of Indapamide can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Loxoprofen.Approved
LuliconazoleThe serum concentration of Indapamide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Indapamide can be increased when combined with Lumacaftor.Approved
LumefantrineIndapamide may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibThe therapeutic efficacy of Indapamide can be decreased when used in combination with Lumiracoxib.Approved, Investigational
MacitentanIndapamide may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe therapeutic efficacy of Indapamide can be decreased when used in combination with Magnesium salicylate.Approved
ManidipineIndapamide may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Indapamide.Approved, Investigational
MasoprocolThe therapeutic efficacy of Indapamide can be decreased when used in combination with Masoprocol.Approved
ME-609ME-609 may increase the hypokalemic activities of Indapamide.Investigational
MebanazineMebanazine may increase the hypotensive activities of Indapamide.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Indapamide is combined with Mecamylamine.Approved
Meclofenamic acidThe therapeutic efficacy of Indapamide can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Indapamide.Approved
Mefenamic acidThe therapeutic efficacy of Indapamide can be decreased when used in combination with Mefenamic acid.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Indapamide.Vet Approved
MeloxicamThe therapeutic efficacy of Indapamide can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Indapamide can be decreased when used in combination with Metamizole.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Indapamide.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Indapamide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Indapamide.Approved, Illicit
MethanthelineThe serum concentration of Indapamide can be increased when it is combined with Methantheline.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Indapamide.Approved
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Indapamide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Indapamide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Indapamide is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Indapamide.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Indapamide.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the orthostatic hypotensive activities of Indapamide.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Indapamide.Approved, Vet Approved
MetipranololThe risk or severity of adverse effects can be increased when Indapamide is combined with Metipranolol.Approved
MetixeneThe serum concentration of Indapamide can be increased when it is combined with Metixene.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Indapamide.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Indapamide.Approved, Investigational
MetyrosineIndapamide may increase the hypotensive activities of Metyrosine.Approved
MibefradilIndapamide may increase the hypotensive activities of Mibefradil.Withdrawn
MifepristoneMifepristone may increase the QTc-prolonging activities of Indapamide.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Indapamide.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Indapamide.Approved
MilnacipranMilnacipran may increase the hyponatremic activities of Indapamide.Approved
MinaprineMinaprine may increase the hypotensive activities of Indapamide.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Indapamide.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Indapamide.Approved, Investigational
MitotaneThe serum concentration of Indapamide can be decreased when it is combined with Mitotane.Approved
MizoribineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Indapamide.Approved
ModafinilThe serum concentration of Indapamide can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Indapamide.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Indapamide.Approved
MometasoneMometasone may increase the hypokalemic activities of Indapamide.Approved, Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Indapamide.Approved, Investigational
MoxifloxacinIndapamide may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineIndapamide may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe therapeutic efficacy of Indapamide can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Indapamide can be decreased when used in combination with Mycophenolic acid.Approved
N-butylscopolammonium bromideThe serum concentration of Indapamide can be increased when it is combined with N-butylscopolammonium bromide.Vet Approved
NabiloneThe risk or severity of adverse effects can be increased when Indapamide is combined with Nabilone.Approved, Investigational
NabumetoneThe therapeutic efficacy of Indapamide can be decreased when used in combination with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Indapamide is combined with Nadolol.Approved
NafamostatThe therapeutic efficacy of Indapamide can be decreased when used in combination with Nafamostat.Investigational
NafcillinThe serum concentration of Indapamide can be decreased when it is combined with Nafcillin.Approved
NaftifineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Naftifine.Approved
NaftopidilIndapamide may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Indapamide.Approved
NaproxenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Naproxen.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Indapamide.Approved, Investigational
NCX 1022NCX 1022 may increase the hypokalemic activities of Indapamide.Investigational
NCX 4016The therapeutic efficacy of Indapamide can be decreased when used in combination with NCX 4016.Investigational
NebivololThe risk or severity of adverse effects can be increased when Indapamide is combined with Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Indapamide can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Indapamide can be decreased when combined with Nelfinavir.Approved
NepafenacThe therapeutic efficacy of Indapamide can be decreased when used in combination with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Indapamide is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Indapamide can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Indapamide can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Indapamide.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Indapamide.Approved
NicorandilNicorandil may increase the hypotensive activities of Indapamide.Approved
NifedipineThe risk or severity of adverse effects can be increased when Indapamide is combined with Nifedipine.Approved
Niflumic AcidThe therapeutic efficacy of Indapamide can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineIndapamide may increase the hypotensive activities of Niguldipine.Experimental
NilotinibIndapamide may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilvadipineIndapamide may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Indapamide.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Indapamide.Approved
NitrendipineIndapamide may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Indapamide is combined with Nitric Oxide.Approved
NitroaspirinThe therapeutic efficacy of Indapamide can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Indapamide.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Indapamide.Approved
NorepinephrineNorepinephrine may increase the hypokalemic activities of Indapamide.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Indapamide.Approved, Illicit
NVA237The serum concentration of Indapamide can be increased when it is combined with NVA237.Investigational
ObinutuzumabIndapamide may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Indapamide.Withdrawn
OfloxacinIndapamide may increase the QTc-prolonging activities of Ofloxacin.Approved
OlaparibThe metabolism of Indapamide can be decreased when combined with Olaparib.Approved
Oleoyl estroneOleoyl estrone may increase the hypokalemic activities of Indapamide.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Indapamide.Approved, Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Indapamide.Approved
OlopatadineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Olsalazine.Approved
OmapatrilatIndapamide may increase the hypotensive activities of Omapatrilat.Investigational
OndansetronIndapamide may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Indapamide.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Indapamide.Approved
OrgoteinThe therapeutic efficacy of Indapamide can be decreased when used in combination with Orgotein.Vet Approved
OrphenadrineThe serum concentration of Indapamide can be increased when it is combined with Orphenadrine.Approved
OsimertinibThe serum concentration of Indapamide can be increased when it is combined with Osimertinib.Approved
OuabainThe risk or severity of adverse effects can be increased when Indapamide is combined with Ouabain.Approved
OxaprozinThe therapeutic efficacy of Indapamide can be decreased when used in combination with Oxaprozin.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Indapamide is combined with Oxcarbazepine.Approved
OxprenololIndapamide may increase the hypotensive activities of Oxprenolol.Approved
OxybutyninThe serum concentration of Indapamide can be increased when it is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Indapamide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Indapamide.Approved, Investigational, Vet Approved
OxyphenbutazoneThe therapeutic efficacy of Indapamide can be decreased when used in combination with Oxyphenbutazone.Withdrawn
OxyphenoniumThe serum concentration of Indapamide can be increased when it is combined with Oxyphenonium.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Indapamide is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Indapamide can be increased when it is combined with Palbociclib.Approved
PaliperidoneIndapamide may increase the QTc-prolonging activities of Paliperidone.Approved
PancuroniumThe serum concentration of Indapamide can be increased when it is combined with Pancuronium.Approved
PanobinostatIndapamide may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Indapamide is combined with Papaverine.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Indapamide.Approved
ParecoxibThe therapeutic efficacy of Indapamide can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Indapamide.Approved
ParicalcitolIndapamide may increase the hypercalcemic activities of Paricalcitol.Approved, Investigational
ParoxetineParoxetine may increase the hyponatremic activities of Indapamide.Approved, Investigational
PazopanibIndapamide may increase the QTc-prolonging activities of Pazopanib.Approved
PenbutololThe risk or severity of adverse effects can be increased when Indapamide is combined with Penbutolol.Approved, Investigational
PentamidineIndapamide may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Indapamide.Approved, Vet Approved
PentobarbitalThe metabolism of Indapamide can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe serum concentration of Indapamide can be increased when it is combined with Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Indapamide.Approved, Investigational
PerflutrenIndapamide may increase the QTc-prolonging activities of Perflutren.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Indapamide.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Indapamide.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Indapamide.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Indapamide.Approved, Withdrawn
PheniprazinePheniprazine may increase the hypotensive activities of Indapamide.Withdrawn
PhenobarbitalThe metabolism of Indapamide can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineIndapamide may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Indapamide.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Indapamide.Approved
PhenylbutazoneThe therapeutic efficacy of Indapamide can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Indapamide.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Indapamide can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe therapeutic efficacy of Indapamide can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PimozideIndapamide may increase the QTc-prolonging activities of Pimozide.Approved
PinacidilIndapamide may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Indapamide is combined with Pindolol.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Indapamide.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Indapamide is combined with Pipamperone.Approved
PipecuroniumThe serum concentration of Indapamide can be increased when it is combined with Pipecuronium.Approved
PirbuterolPirbuterol may increase the hypokalemic activities of Indapamide.Approved
PirenzepineThe serum concentration of Indapamide can be increased when it is combined with Pirenzepine.Approved
PirfenidoneThe therapeutic efficacy of Indapamide can be decreased when used in combination with Pirfenidone.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Indapamide.Investigational
PirlindolePirlindole may increase the hypotensive activities of Indapamide.Approved
PiroxicamThe therapeutic efficacy of Indapamide can be decreased when used in combination with Piroxicam.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Indapamide.Withdrawn
PolythiazideIndapamide may increase the hypotensive activities of Polythiazide.Approved
PosaconazoleThe metabolism of Indapamide can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Indapamide is combined with Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Indapamide.Approved, Investigational
PrasteronePrasterone may increase the hypokalemic activities of Indapamide.Approved, Nutraceutical
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Indapamide.Approved
PrednicarbatePrednicarbate may increase the hypokalemic activities of Indapamide.Approved
PrednisolonePrednisolone may increase the hypokalemic activities of Indapamide.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Indapamide.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Indapamide.Experimental
PrimaquineIndapamide may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Indapamide can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideIndapamide may increase the QTc-prolonging activities of Procainamide.Approved
ProcaterolProcaterol may increase the hypokalemic activities of Indapamide.Approved
ProcyclidineThe serum concentration of Indapamide can be increased when it is combined with Procyclidine.Approved
PromazineIndapamide may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PropacetamolThe therapeutic efficacy of Indapamide can be decreased when used in combination with Propacetamol.Approved
PropafenoneIndapamide may increase the QTc-prolonging activities of Propafenone.Approved
PropanthelineThe serum concentration of Indapamide can be increased when it is combined with Propantheline.Approved
PropiverineThe serum concentration of Indapamide can be increased when it is combined with Propiverine.Investigational
PropofolThe risk or severity of adverse effects can be increased when Indapamide is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Indapamide.Approved, Investigational
PTC299The therapeutic efficacy of Indapamide can be decreased when used in combination with PTC299.Investigational
QuetiapineIndapamide may increase the QTc-prolonging activities of Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Indapamide is combined with Quinapril.Approved, Investigational
QuinidineIndapamide may increase the QTc-prolonging activities of Quinidine.Approved
QuinineIndapamide may increase the QTc-prolonging activities of Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Indapamide.Approved
RanolazineThe metabolism of Indapamide can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Indapamide.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Indapamide.Approved
RemikirenRemikiren may increase the hypotensive activities of Indapamide.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Indapamide.Approved, Investigational
RescinnamineIndapamide may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Indapamide.Approved
ResveratrolThe therapeutic efficacy of Indapamide can be decreased when used in combination with Resveratrol.Experimental, Investigational
RifabutinThe metabolism of Indapamide can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Indapamide can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Indapamide can be increased when combined with Rifapentine.Approved
RilmenidineIndapamide may increase the hypotensive activities of Rilmenidine.Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Indapamide.Approved
RiociguatThe risk or severity of adverse effects can be increased when Indapamide is combined with Riociguat.Approved
RisperidoneIndapamide may increase the hypotensive activities of Risperidone.Approved, Investigational
RitodrineRitodrine may increase the hypokalemic activities of Indapamide.Approved
RitonavirThe metabolism of Indapamide can be decreased when combined with Ritonavir.Approved, Investigational
RituximabIndapamide may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe therapeutic efficacy of Indapamide can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Indapamide is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Indapamide is combined with Ropivacaine.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Indapamide.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Indapamide is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Indapamide is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Indapamide.Withdrawn
SalbutamolSalbutamol may increase the hypokalemic activities of Indapamide.Approved, Vet Approved
SalicylamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Indapamide can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Indapamide.Approved
SalsalateThe therapeutic efficacy of Indapamide can be decreased when used in combination with Salsalate.Approved
SaprisartanIndapamide may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Indapamide can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Indapamide.Approved
ScopolamineThe serum concentration of Indapamide can be increased when it is combined with Scopolamine.Approved
Scopolamine butylbromideThe serum concentration of Indapamide can be increased when it is combined with Scopolamine butylbromide.Approved
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Indapamide.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Indapamide.Approved, Investigational, Vet Approved
SelexipagIndapamide may increase the hypotensive activities of Selexipag.Approved
SeratrodastThe therapeutic efficacy of Indapamide can be decreased when used in combination with Seratrodast.Approved, Investigational
SertralineSertraline may increase the hyponatremic activities of Indapamide.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Indapamide is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Indapamide.Approved, Investigational
SiltuximabThe serum concentration of Indapamide can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Indapamide can be increased when it is combined with Simeprevir.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Indapamide.Approved, Investigational
SitaxentanIndapamide may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Indapamide is combined with Sodium Nitrite.Approved
SolifenacinThe serum concentration of Indapamide can be increased when it is combined with Solifenacin.Approved
SotalolIndapamide may increase the QTc-prolonging activities of Sotalol.Approved
SpiraprilIndapamide may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Indapamide.Approved
SRT501The therapeutic efficacy of Indapamide can be decreased when used in combination with SRT501.Investigational
St. John's WortThe serum concentration of Indapamide can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Indapamide can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Indapamide is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Indapamide.Approved, Investigational
SulfasalazineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Sulfasalazine.Approved
SulfisoxazoleIndapamide may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulindacThe therapeutic efficacy of Indapamide can be decreased when used in combination with Sulindac.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Indapamide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Indapamide is combined with Sulpiride.Approved
SuprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Suprofen.Approved, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Indapamide.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Indapamide is combined with Tamsulosin.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Indapamide.Approved
TelaprevirThe metabolism of Indapamide can be decreased when combined with Telaprevir.Approved
TelavancinIndapamide may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Indapamide can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Indapamide is combined with Telmisartan.Approved, Investigational
TemocaprilIndapamide may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenoxicamThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Indapamide is combined with Terazosin.Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Indapamide.Approved
TeriflunomideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Teriflunomide.Approved
TerlipressinIndapamide may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrabenazineIndapamide may increase the QTc-prolonging activities of Tetrabenazine.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Indapamide is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the orthostatic hypotensive activities of Indapamide.Approved, Vet Approved
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Indapamide.Investigational
ThiopentalThiopental may increase the orthostatic hypotensive activities of Indapamide.Approved, Vet Approved
ThioridazineIndapamide may increase the QTc-prolonging activities of Thioridazine.Approved
Tiaprofenic acidThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tiaprofenic acid.Approved
TiboloneIndapamide may increase the hypotensive activities of Tibolone.Approved
TiclopidineThe metabolism of Indapamide can be decreased when combined with Ticlopidine.Approved
TicrynafenIndapamide may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Indapamide.Approved
TinoridineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tinoridine.Investigational
TiotropiumThe serum concentration of Indapamide can be increased when it is combined with Tiotropium.Approved
TixocortolTixocortol may increase the hypokalemic activities of Indapamide.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Indapamide.Approved
TocilizumabThe serum concentration of Indapamide can be decreased when it is combined with Tocilizumab.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Indapamide.Approved
TolazolineTolazoline may increase the hypotensive activities of Indapamide.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Indapamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Indapamide is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Indapamide.Approved
TolterodineThe serum concentration of Indapamide can be increased when it is combined with Tolterodine.Approved, Investigational
TopiramateIndapamide may increase the hypokalemic activities of Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Indapamide.Approved
ToremifeneIndapamide may increase the hypercalcemic activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Indapamide.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Indapamide.Approved
TranilastThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Indapamide.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Indapamide.Approved
TravoprostTravoprost may increase the hypotensive activities of Indapamide.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Indapamide.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Indapamide is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Indapamide.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Indapamide.Approved
TrichlormethiazideIndapamide may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrihexyphenidylThe serum concentration of Indapamide can be increased when it is combined with Trihexyphenidyl.Approved
TrimazosinIndapamide may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanThe serum concentration of Indapamide can be increased when it is combined with Trimethaphan.Approved
Trisalicylate-cholineThe therapeutic efficacy of Indapamide can be decreased when used in combination with Trisalicylate-choline.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Indapamide.Withdrawn
TropicamideThe serum concentration of Indapamide can be increased when it is combined with Tropicamide.Approved
TrospiumThe serum concentration of Indapamide can be increased when it is combined with Trospium.Approved
TubocurarineThe serum concentration of Indapamide can be increased when it is combined with Tubocurarine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Indapamide.Approved, Investigational
UmeclidiniumThe serum concentration of Indapamide can be increased when it is combined with Umeclidinium.Approved
UnoprostoneIndapamide may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe therapeutic efficacy of Indapamide can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Indapamide.Approved, Investigational
VandetanibIndapamide may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the antihypertensive activities of Indapamide.Approved
VecuroniumThe serum concentration of Indapamide can be increased when it is combined with Vecuronium.Approved
VemurafenibIndapamide may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineThe metabolism of Indapamide can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Indapamide.Approved
VilanterolVilanterol may increase the hypokalemic activities of Indapamide.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Indapamide.Approved, Investigational
VinpocetineIndapamide may increase the hypotensive activities of Vinpocetine.Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Indapamide.Approved, Investigational
VoriconazoleThe metabolism of Indapamide can be decreased when combined with Voriconazole.Approved, Investigational
XylometazolineIndapamide may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Indapamide.Approved, Vet Approved
ZaltoprofenThe therapeutic efficacy of Indapamide can be decreased when used in combination with Zaltoprofen.Approved
ZileutonThe therapeutic efficacy of Indapamide can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the hyponatremic activities of Indapamide.Withdrawn
ZiprasidoneIndapamide may increase the QTc-prolonging activities of Ziprasidone.Approved
ZomepiracThe therapeutic efficacy of Indapamide can be decreased when used in combination with Zomepirac.Withdrawn
ZuclopenthixolIndapamide may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals. Magnesium, potassium and zinc needs increased.
References
Synthesis Reference

Chunyi Yeh, Yi-Lung Wang, Ya-Sheng Yang, Ya-Ching Chang Chein, “Oral sustained-release pharmaceutical composition of indapamide, production and use thereof.” U.S. Patent US20060182803, issued August 17, 2006.

US20060182803
General References
  1. Dong DL, Wang QH, Yue P, Jiao JD, Gu RM, Yang BF: Indapamide induces apoptosis of GH3 pituitary cells independently of its inhibition of voltage-dependent K+ currents. Eur J Pharmacol. 2006 Apr 24;536(1-2):78-84. Epub 2006 Mar 2. [PubMed:16556441 ]
External Links
ATC CodesC03BA11C09BX01
AHFS Codes
  • 40:28.24
PDB EntriesNot Available
FDA labelDownload (322 KB)
MSDSDownload (72.7 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8868
Caco-2 permeable-0.5529
P-glycoprotein substrateNon-substrate0.6859
P-glycoprotein inhibitor INon-inhibitor0.9158
P-glycoprotein inhibitor IINon-inhibitor0.9179
Renal organic cation transporterNon-inhibitor0.8575
CYP450 2C9 substrateNon-substrate0.5265
CYP450 2D6 substrateNon-substrate0.7924
CYP450 3A4 substrateNon-substrate0.519
CYP450 1A2 substrateInhibitor0.582
CYP450 2C9 inhibitorNon-inhibitor0.5775
CYP450 2D6 inhibitorNon-inhibitor0.8151
CYP450 2C19 inhibitorNon-inhibitor0.6572
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7471
Ames testNon AMES toxic0.6869
CarcinogenicityNon-carcinogens0.7674
BiodegradationNot ready biodegradable0.9862
Rat acute toxicity2.0823 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.986
hERG inhibition (predictor II)Non-inhibitor0.8804
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Actavis elizabeth llc
  • Alphapharm party ltd
  • Cadista pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Sanofi aventis us llc
Packagers
Dosage forms
FormRouteStrength
TabletOral
TabletOral1.25 mg/1
TabletOral2.5 mg/1
Tablet, film coatedOral1.25 mg/1
Tablet, film coatedOral2.5 mg/1
TabletOral2.5 mg
TabletOral1.25 mg
Prices
Unit descriptionCostUnit
Indapamide 2.5 mg tablet0.85USD tablet
Indapamide 1.25 mg tablet0.69USD tablet
Lozide 2.5 mg Tablet0.55USD tablet
Apo-Indapamide 2.5 mg Tablet0.31USD tablet
Mylan-Indapamide 2.5 mg Tablet0.31USD tablet
Novo-Indapamide 2.5 mg Tablet0.31USD tablet
Nu-Indapamide 2.5 mg Tablet0.31USD tablet
Pms-Indapamide 2.5 mg Tablet0.31USD tablet
Apo-Indapamide 1.25 mg Tablet0.2USD tablet
Mylan-Indapamide 1.25 mg Tablet0.2USD tablet
Pms-Indapamide 1.25 mg Tablet0.2USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point160-162U.S.Patent 3,565,911.
water solubility75 mg/LNot Available
logP2.2Not Available
pKa8.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0342 mg/mLALOGPS
logP2.52ALOGPS
logP2.64ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)8.85ChemAxon
pKa (Strongest Basic)0.097ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area92.5 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity103.31 m3·mol-1ChemAxon
Polarizability36.34 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzenesulfonamides
Direct ParentBenzenesulfonamides
Alternative Parents
Substituents
  • 4-halobenzoic acid or derivatives
  • Benzenesulfonamide
  • Indole or derivatives
  • Benzoic acid or derivatives
  • Benzamide
  • Benzoyl
  • Halobenzene
  • Chlorobenzene
  • Aryl halide
  • Aryl chloride
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Carboxylic acid hydrazide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Potassium channel that plays an important role in a number of tissues, including heart, inner ear, stomach and colon (By similarity) (PubMed:10646604). Associates with KCNE beta subunits that modulates current kinetics (By similarity) (PubMed:9312006, PubMed:9108097, PubMed:8900283, PubMed:10646604, PubMed:11101505, PubMed:19687231). Induces a voltage-dependent by rapidly activating and slowly ...
Gene Name:
KCNQ1
Uniprot ID:
P51787
Molecular Weight:
74697.925 Da
References
  1. Ohya S, Asakura K, Muraki K, Watanabe M, Imaizumi Y: Molecular and functional characterization of ERG, KCNQ, and KCNE subtypes in rat stomach smooth muscle. Am J Physiol Gastrointest Liver Physiol. 2002 Feb;282(2):G277-87. [PubMed:11804849 ]
  2. Li RA, Miake J, Hoppe UC, Johns DC, Marban E, Nuss HB: Functional consequences of the arrhythmogenic G306R KvLQT1 K+ channel mutant probed by viral gene transfer in cardiomyocytes. J Physiol. 2001 May 15;533(Pt 1):127-33. [PubMed:11351021 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Telethonin binding
Specific Function:
Ancillary protein that assembles as a beta subunit with a voltage-gated potassium channel complex of pore-forming alpha subunits. Modulates the gating kinetics and enhances stability of the channel complex. Assembled with KCNB1 modulates the gating characteristics of the delayed rectifier voltage-dependent potassium channel KCNB1 (PubMed:19219384). Assembled with KCNQ1/KVLQT1 is proposed to for...
Gene Name:
KCNE1
Uniprot ID:
P15382
Molecular Weight:
14674.66 Da
References
  1. Ohya S, Asakura K, Muraki K, Watanabe M, Imaizumi Y: Molecular and functional characterization of ERG, KCNQ, and KCNE subtypes in rat stomach smooth muscle. Am J Physiol Gastrointest Liver Physiol. 2002 Feb;282(2):G277-87. [PubMed:11804849 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Sun H, Moore C, Dansette PM, Kumar S, Halpert JR, Yost GS: Dehydrogenation of the indoline-containing drug 4-chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide (indapamide) by CYP3A4: correlation with in silico predictions. Drug Metab Dispos. 2009 Mar;37(3):672-84. doi: 10.1124/dmd.108.022707. Epub 2008 Dec 12. [PubMed:19074530 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23